L-030

Lurasidone hydrochloride solution

1.0 mg/mL in methanol (as free base), ampule of 1 mL, certified reference material, Cerilliant^®

• 经验公式（希尔记法）: C₂₈H₃₆N₄O₂S · HCl
• CAS号: 367514-88-3
• 分子量: 529.14
• EC號碼: 200-659-6
• MDL號碼: MFCD18917095
• 分類程式碼代碼: 41116107
• PubChem物質ID: 329817348
• NACRES: NA.24

属性

• 等級: certified reference material
• 品質等級: 300
• 形狀: liquid
• 特點: Snap-N-Spike^®/Snap-N-Shoot^®
• 包裝: ampule of 1 mL
• 製造商／商標名: Cerilliant^®
• 濃度: 1.0 mg/mL in methanol (as free base)
• 技術: gas chromatography (GC): suitable; liquid chromatography (LC): suitable
• 應用: clinical testing
• 形式: single component solution
• 儲存溫度: −20°C
• SMILES 字串: Cl.O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1C[C@@H]4CCCC[C@H]4CN5CCN(CC5)c6nsc7ccccc67
• InChI: 1S/C28H36N4O2S.ClH/c33-27-24-18-9-10-19(15-18)25(24)28(34)32(27)17-21-6-2-1-5-20(21)16-30-11-13-31(14-12-30)26-22-7-3-4-8-23(22)35-29-26;/h3-4,7-8,18-21,24-25H,1-2,5-6,9-17H2;1H/t18-,19+,20-,21-,24+,25-;/m0./s1
• InChI 密鑰: NEKCRUIRPWNMLK-SCIYSFAVSA-N
• 基因資訊: human ... DRD2(1813) , HTR2A(3356)

说明

一般說明

A certified solution standard suitable for use in LC/MS or GC/MS applications for clinical toxicology, forensic analysis, pharmaceutical research, or urine drug testing. Marketed under the trade name Latuda^®, lurasidone is a new atypical antipsychotic developed for the treatment of schizophrenia.

應用

• LurasiDonein Bipolar Depression Research: A study explored the pharmacodynamic properties of lurasidone, hypothesizing its efficacy in acute bipolar depression. This research provides a deep dive into the mechanistic actions of lurasidone, enhancing understanding in neuropharmacological studies and aiding in the development of more effective treatments for bipolar disorder (Fountoulakis et al., 2024).


• Quantification of LurasiDonein Clinical Samples: Development and validation of a liquid chromatography-tandem mass spectrometry method for quantifying lurasiDonein dried blood spot samples was reported. This method facilitates easier and less invasive monitoring of lurasiDonelevels in patients, crucial for effective pharmacological research and ensuring therapeutic efficacy in treatment regimes (Rajadhyaksha and Londhe, 2023).


• Novel Methodologies in Clinical Trials: Research introduced a novel method for deriving adverse event prevalence in randomized controlled trials, which could potentially improve the understanding of the benefit-risk ratio of drugs including lurasidone. This approach is particularly relevant for drug labels and regulatory submissions, ensuring safer and more effective clinical outcomes (Piacentino et al., 2024).


• Pharmacological Properties of Lurasidone: A study investigated how lurasiDoneblocks the voltage-gated potassium channels of coronary arterial smooth muscle cells, offering insights into its broader pharmacological impacts. This research is vital for assessing potential cardiovascular side effects and optimizing dosing strategies to mitigate risks in patients treated with lurasiDone(Zhuang et al., 2023).

法律資訊

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany

Latuda is a registered trademark of Dainippon Sumitomo Pharma Co., Ltd.

Snap-N-Shoot is a registered trademark of Cerilliant Corporation

Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

安全信息

• 象形圖: GHS02,GHS06,GHS08
• 訊號詞: Danger
• 危險聲明: H225,H301 + H311 + H331,H370
• 防範說明: P210 - P280 - P301 + P310 + P330 - P302 + P352 + P312 - P304 + P340 + P311
• 危險分類: Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1
• 標靶器官: Eyes
• 儲存類別代碼: 3 - Flammable liquids
• 水污染物質分類（WGK）: WGK 1
• 閃點（°F）: 49.5 °F - closed cup
• 閃點（°C）: 9.7 °C - closed cup